| 3.23 Data as of Jun 18 |  +0.10 / +3.19%Today’s Change | 1.95 Today|||52-Week Range 4.50 | -7.18% Year-to-Date |
| Ovarian Cancer Drug Half Way There Jun 13 / MotleyFool.com | Amgen Drug Delays Ovarian Cancer Re-Growth, Survival Benefit Unclear Jun 12 / TheStreet.com |
| Previous close | 3.13 |
| Today’s open | 3.15 |
| Day’s range | -- - -- |
| Volume | 688,546 |
| Average volume (3 months) | 737,259 |
| Market cap | $352.7M |
| Dividend yield | -- |
| Earnings growth (last year) | +14.29% |
| Earnings growth (this year) | +9.17% |
| Earnings growth (next 5 years) | +4.00% |
| Revenue growth (last year) | +12.13% |
| P/E ratio | NM |
| Price/Sales | 6.30 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| AMRIAlbany Molecular Res... | -0.13 | -1.07% |
| QLTIQLT Inc | -0.14 | -1.66% |
| NVIVInVivo Therapeutics ... | -0.11 | -2.75% |
| SGMOSangamo BioSciences ... | +0.19 | +2.38% |
| Next reporting date | July 24, 2013 |
| EPS forecast (this quarter) | -$0.06 |
| Annual revenue (last year) | $54.7M |
| Annual profit (last year) | -$29.3M |
| Net profit margin | -53.55% |
Sector Health Technology |
Industry Biotechnology |
Chairman Henry E. Blair |
President, Chief Executive Officer & Director Gustav A. Christensen, MBA |
Corporate headquarters Burlington, Massachusetts |
.
